Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
Status:
Terminated
Trial end date:
2019-02-05
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in
patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia
(TRS)